Novo Nordisk
About
Novo Nordisk is a global healthcare company based in Denmark, listed with the Kendall Square Association as part of the Cambridge life sciences community. Its roots lie in diabetes care, where it has more than a century of experience, and that heritage has expanded into treatments for other serious chronic conditions, including obesity, rare bleeding disorders and growth hormone-related disorders. The company emphasizes seeing the whole person when developing treatments and patient support.
Novo Nordisk is widely known for its semaglutide medicines, including Wegovy for obesity, and research presented at EASD 2026 showed Wegovy reduced liver fat to normal levels in nine out of ten adults with obesity and excess liver fat. Its pipeline also includes CagriSema, an investigational obesity and diabetes drug reported to reduce “food noise,” and denecimig, for which it has filed a Biologics License Application in the United States.
What to Know
- Novo Nordisk traces its origins to 1923 in Denmark.
- Its diabetes medicines include insulin products and Ozempic.
- Company headquarters is in Bagsværd, near Copenhagen.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.